PHARMALEX
PHARMALEX, a leading global provider of regulatory affairs, quality assurance, and compliance services, is headquartered in Great Britain. Founded in 1998, the company has established a strong presence across Europe, North America, and Asia, catering to the pharmaceutical, biotechnology, and medical device industries. With a focus on delivering tailored solutions, PHARMALEX offers a comprehensive range of services, including clinical trial management, market access strategies, and post-market surveillance. Their commitment to quality and regulatory excellence has positioned them as a trusted partner for clients navigating complex compliance landscapes. Recognised for their innovative approach and industry expertise, PHARMALEX continues to achieve significant milestones, solidifying their reputation as a key player in the life sciences sector.
DitchCarbon Score
How does PHARMALEX's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PHARMALEX's score of 6 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PHARMALEX's reported carbon emissions
In 2021, PHARMALEX reported total carbon emissions of approximately 1,487,150 kg CO2e. This figure includes emissions across all three scopes: Scope 1 emissions were about 27,080 kg CO2e, Scope 2 emissions totalled approximately 97,560 kg CO2e, and Scope 3 emissions accounted for a significant 1,416,510 kg CO2e. Notably, the largest contributors to Scope 3 emissions were purchased goods and services, which represented about 1,007,000 kg CO2e, followed by employee commuting at approximately 333,000 kg CO2e and business travel at around 62,000 kg CO2e. Despite the substantial emissions reported, PHARMALEX has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments or science-based targets suggests that while the company is aware of its emissions profile, it may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | |
|---|---|
| Scope 1 | 27,080 |
| Scope 2 | 97,560 |
| Scope 3 | 1,416,510 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PHARMALEX is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
